Billions of dollars already invested for coronavirus vaccines in the USA. It is here that the offers are
So far, as part of Operation Warp Speed, the federal government has made agreements with a number of pharmaceutical companies that have measured about $10.79 billion. The project aims to include at least 300 million doses of a vaccine against coronavirus by January 2021.
Moderna, Johnson & Johnson, Pfizer and BioNTech, Sanofi and GlaxoSmithKline, Novavax and AstraZeneca all provided funding for their vaccines from the surgery.
The United States has contributed billions to create a coronavirus vaccine that has infected more than 5.1 million people around the world, locking up at least 800 million doses as soon as the immunizations are approved later this year or early next year.
So far, the deal with a handful of pharmaceutical companies has peaked at about $10.79 billion as part of Operation Warp Pace, a initiative led by many federal government agencies to promote the production, produce, and delivery of coronavirus vaccines and treatments.
The project aims to include at least 300 million doses of a vaccine against coronavirus by January 2021. In most of the agreements, HHS says that if part of a vaccine campaign, the vaccines will be given to American people for free. The program, once the vaccines are accepted, aims to deliver them to as many people as possible. The federal government has said it would pay delivery costs but health care providers can charge the vaccine for administration.
"We 'd probably have tens of millions of doses available at the beginning of next year," Dr Anthony Fauci, director of the National Institute for Allergy and Infectious Diseases, told reporters on a conference call.
"I think you 'd have vaccines that would be widely available as we get into 2021, several months in,," Fauci said.
Researchers believe some of the top candidates for the vaccine are now being developed "at risk," meaning the doses are being produced and prepared for delivery until official U.S. approval. Food and Medication Administration.
"To ensure fast delivery, we are investing in designing and producing the top six candidates for the vaccines. The military is ready to go, they 're ready to bring a vaccine to the Americans as soon as it is completely approved by the FDA and we're very close to that approval, "said President Donald Trump at a White House Tuesday press conference.
The U.S. is only obligated to pay the next funding traunch if the Food and Drug Administration approves the vaccines.
Here's where the offers so far stand:
New Edition
On Aug. 11, Trump said the U.S. government had reached an agreement with Moderna based in Massachusetts for 100 million doses of its leading vaccine candidate mRNA-1273.
According to a separate statement by Moderna, the agreement gives the federal government the right to purchase up to 400 million additional doses. The company said the transaction worth up to $1.53 billion.
The U.S. has now spent $955 million in the production of the Moderna vaccine, taking its overall investment to $2.48 billion , the company said.
The candidate for the Moderna vaccine is in late-stage clinical trials. Previously the company had said it could expect results as early as October.
Smith and Smith:
On Aug. 5, HHS revealed it had reached an agreement with Janssen, the pharmaceutical company of J&J, worth approximately $1 billion per 100 million doses of its vaccine.
According to the announcement, the deal is giving the federal government the option to order an additional 200 million doses.
The US paid J&J $456 million earlier this year to improve the vaccine.
J&J 's experimental vaccine is currently undergoing early-stage clinical trials, and late-stage human trials are scheduled to begin in September, executives have said.
Sanofi and GlaxoSmithKline
On July 31, Sanofi and GSK, co-producing a vaccine, announced that HHS would pay up to $2.1 billion for producing and supplying 100 million doses of their possible candidate.
The US will have the option of buying an additional 500 million doses, the firms said.
Less than half of the $2.1 billion investment will be spent on future vaccine production while the remaining dollars will be spent on producing the first 100 million doses, the businesses said.
Pfizer and BioNTech
On 22 July, Germany-based BioNTech and Pfizer revealed that the US agreed to purchase up to $1.95 billion in 100 million doses of their future coronavirus vaccine.
The deal allows the U.S. to procure an additional 500 million doses of the vaccine, the companies said.
The firms are working together on four candidates for the vaccines. Late-stage human trials started in late July with the most advanced, named BNT162b1.
The companies said they're planning to bring up to 100 million doses by the end of 2020 and around 1.3 billion doses by the end of 2021.
Novavax
On July 7, HHS revealed it had signed a $1.6 billion agreement with Maryland-based drug maker Novavax to support the company with trials and manufacturing.
The federal government said that once approved as part of the contract, Novavax would supply 100 million doses of its experimental coronavirus vaccine to the US.
The vaccine Novavax, called NVX-CoV2373, developed a promising immune response in early-stage clinical trials and could start late-stage trials as early as October.
The company said it hopes to begin supplying 100 million doses of the vaccine before the start of next year.
AstraZeneca
On May 21 HHS announced it will pay AstraZeneca up to $1.2 billion for its experimental vaccine produced at the University of Oxford alongside researchers.
As part of the commitment the U.S. will provide at least 300 million doses of the vaccine, HHS said.
The UK, in June. Based company said it is planning to produce 2 billion doses of its AZD1222 vaccine, and will start distributing doses in the fall.
On July 20, the company revealed promising early-stage human trial results and began late-stage human trials in the United Kingdom, Brazil and South Africa.